# Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

> **NCT07102719** · PHASE1 · COMPLETED · sponsor: **Handok Inc.** · enrollment: 40 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** HD-P023
- **DRUG:** Teneligliptin and Empagliflozin

## Key facts

- **NCT ID:** NCT07102719
- **Lead sponsor:** Handok Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-10
- **Primary completion:** 2025-10-20
- **Final completion:** 2025-10-20
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07102719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07102719, "Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07102719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*